ArticleHuman vaccines & immunotherapeutics2022

A multi-centre, post-marketing surveillance study of Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar TCV®) in India.

Raghu Reddy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.